key: cord-0270701-6t5w1o02
authors: Tuite, A.; Lee, N.; Fisman, D.
title: Timing of Breakthrough Infection Risk After Vaccination Against SARS-CoV-2
date: 2022-01-05
journal: nan
DOI: 10.1101/2022.01.04.22268773
sha: faeab8bc2c2c0a92a5937ea834f16212adff3d65
doc_id: 270701
cord_uid: 6t5w1o02

Background: Provision of safe and effective vaccines has been a remarkable public health achievement during the SARS-CoV-2 pandemic. The effectiveness and durability of protection of the first two doses of SARS-CoV-2 vaccines is an important area for study, as are questions related to optimal dose combinations and dosing intervals. Methods: We performed a case-cohort study to generate real-world evidence on efficacy of first and second dose of SARS-CoV-2 vaccines, using a population-based case line list and vaccination database for the province of Ontario, Canada between December 2020 and October 2021. Risk of infection after vaccination was evaluated in all laboratory-confirmed vaccinated SARS-CoV-2 cases, and a 2% sample of vaccinated controls, evaluated using survival analytic methods, including construction of Cox proportional hazards models. Vaccination status was treated as a time-varying covariate. Results: First and second doses of SARS-CoV-2 vaccine markedly reduced risk of infection (first dose efficacy 68%, 95% CI 67% to 69%; second dose efficacy 88%, 95% CI 87 to 88%). In multivariable models, extended dosing intervals were associated with lowest risk of breakthrough infection (HR for redosing 0.64 (95% CI 0.61 to 0.67) at 6-8 weeks). Heterologous vaccine schedules that mixed viral vector vaccine first doses with mRNA second doses were significantly more effective than mRNA only vaccines. Risk of infection largely vanished during the time period 4-6 months after the second vaccine dose, but rose markedly thereafter. Interpretation: A case-cohort design provided an efficient means to identify strong protective effects associated with SARS-CoV-2 vaccination, particularly after the second dose of vaccine. However, this effect appeared to wane once more than 6 months had elapsed since vaccination. Heterologous vaccination and extended dosing intervals improved the durability of immune response.

In multivariable models, extended dosing intervals were associated with lowest risk of 38 breakthrough infection (HR for redosing 0.64 (95% CI 0.61 to 0.67) at 6-8 weeks). 39

Heterologous vaccine schedules that mixed viral vector vaccine first doses with mRNA second 40 doses were significantly more effective than mRNA only vaccines. Risk of infection largely 41 vanished during the time period 4-6 months after the second vaccine dose, but rose markedly 42 thereafter. 43

Interpretation: A case-cohort design provided an efficient means to identify strong protective 44 effects associated with SARS-CoV-2 vaccination, particularly after the second dose of vaccine. 45 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268773 doi: medRxiv preprint Introduction 50 51

The rapid introduction of highly effective vaccines against SARS-CoV-2 represents a 52 remarkable scientific achievement amidst the current global pandemic (1) . It has been estimated 53 that these vaccines have averted hundreds of thousands of deaths (2, 3) . While mRNA vaccines 54 represent the first application of a novel and highly immunogenic vaccine construct, viral vector 55 vaccines have also been extremely effective in preventing severe illness and death (4) . The 56 introduction of novel vaccines against a virus that has been recognized for only two years (5) , 57 means that there is of necessity a great deal of uncertainty related to their application. The 58 relative protection afforded by vaccines against emerging variants of concern (6), vaccine safety 59 (7, 8) , the immunogenicity of mixed vaccine schedules (9) , optimal spacing between 60 administration of doses (10) , the number of doses required for a full primary series (11) , and the 61 necessity of future boosting (12) , are all the subject of active study. 62

The Canadian province of Ontario represents a large (population 14.6 million) and 63 diverse jurisdiction, with high levels of 2-dose SARS-CoV-2 vaccine coverage (approximately 64 77% as of December 2021) (13, 14) . The province has made use of several different vaccine 65 formulations, predominantly BNT162b2 (BNT/Pfizer, "Cominrty"), mRNA-1273 (Moderna, 66 "SpikeVax"), and ChAdOX1-S (AstraZeneca, "Covishield"). Ontario's vaccination program has 67 prioritized risk groups over time. For example, the program initially focussed on vaccinating 68 residents of long-term care facilities and health-care workers (15). Once higher risk groups were 69 vaccinated, eligibility was expanded using a descending age-based approach. The province also 70 consciously chose to offer extended dosing intervals to lower risk populations, due to supply 71 constraints and the potential advantages of rapid, maximal coverage with first doses of vaccine 72 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268773 doi: medRxiv preprint (16) . Pediatric vaccination programs for those aged 5 to 11 years were introduced in in late 73

November 2021 (17) . 74

Beginning in autumn 2021, third doses have been offered to a growing list of individuals 75 identified as being at elevated risk due to age, medical comorbidity or congregate living 76 residence. Although there was some evidence suggesting that the use of prolonged dosing 77 intervals in the primary series had resulted in durable immunity that made third doses 78 unnecessary (18) , the province expanded access to third vaccine to all aged 50 and over 79

December 2021 (19) . In late December, the rapid spread of the Omicron variant of concern in the 80 province resulted in an expansion of third dose eligibility to all aged 18 and over who received 81 their second dose at least 3 months previously. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268773 doi: medRxiv preprint

We created a cohort of individuals who received vaccination against SARS-CoV-2 in 98

Ontario, without record of infection prior to the date of receipt of first vaccine dose. We 99 included all reported cases of infection meeting these criteria, as well as a 2% random sample of 100 vaccinated individuals with no record of infection. Cases were identified in the Province's Case 101

and Contact Management (CCM) database as described elsewhere (20, 21); we included only 102 cases with a unique "pseudo-health card number", which permitted linkage with the provincial 103 vaccination database. Vaccination information on cases and controls was extracted from the 104 Province's COVaxON dataset (21) , which includes dosage dates, vaccines used, basic 105 demographic information, and fields on indication for vaccination, including residence in a 106 congregate setting (including residence in a nursing home, retirement community, or other 107 congregate setting), priority health condition, and healthcare worker status. As with cases, the 108 pool of potential controls was limited to individuals with a pseudo-health card number. A flow 109 diagram outlining creation of the cohort is presented in Figure 1 . consistency with Canadian public health authorities (24) . 116

Analysis 117 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268773 doi: medRxiv preprint 7 We performed a case-cohort analysis using survival analytic methods. As person time data were 118 available, we were able to estimate hazard ratios directly using Cox proportional hazards models, 119 rather than approximate such ratios via risk set sampling. Controls were reweighted by a factor 120 of 50 to account for 2% selection probability. We stratified within-person time at risk according 121 to an individual's vaccination status, which was treated as a time-varying covariate. 122

We created Cox proportional hazards models including only vaccination as an exposure 123 (unvaccinated, single-dose vaccinated, or fully vaccinated), as well as adjusted models that 124 adjusted for variables that we expected to confound observed vaccine effect. We evaluated the 125 proportional hazards assumption both graphically using log-log plots, and statistically based on 126

Schoenfeld residuals (25). As we found hazards of infection following vaccination to be non-127

proportional through inspection of log-log plots and testing of Schoenberg residuals 128 (Supplementary Figure) , we re-ran our Cox proportional hazards models with time at risk 129 further stratified by 2-month blocks, within a given vaccination status. 130

Lastly, we performed restriction analyses in which we restricted cases individuals with 131 infection due to a non-variant of concern viral strain, to infection with N501Y+ variants of 132 concern (alpha, beta and gamma variants), and to infection with likely delta infection. 133

Classification of likely variant status of the infecting strain was as described previously (21) . We 134 conducted all analyses in Stata version 15.1 using sts, stox and related commands. The study was 135 conducted in accordance with the STROBE guidelines for observational research (26) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 5, 2022. documented priority health condition, residence in a congregate setting, and healthcare worker 144 status, as well as interval between first and second doses ( Table 1) . Crude time to breakthrough 145 infection by vaccination status is presented as a Kaplan-Meier curve (Figure 2) ; vaccination was 146 associated with significant reduction in infection risk, with 2-dose vaccination reducing risk 147 relative to single dose vaccination (P < 0.001 by log-rank test for all comparisons). 148

We constructed a Cox proportional hazards model that included only vaccination status; 149 the hazard ratio for breakthrough infection after a single dose of vaccine was 0.32 (95% CI 0.31 150 to 0.33); after a second dose of vaccine the hazard ratio declined to 0.12 (95% CI 0.12 to 0.13), 151 corresponding to effectiveness of 68% and 88% against infection. We found little change in 152 these after adjusting for potential confounders in multivariable models ( Table 2 Table) . The lowest hazard ratio for 165 breakthrough infection was seen between four and 6 months after second vaccine dose but 166 increased after 6 months of observation (Figure 3) . In exploratory restriction analyses in which 167 we included only cases with non-variant of concern infection, cases with N501Y+ infection 168 (alpha, beta or gamma variants), or cases with delta variant infection, we found significant 169 protection against breakthrough infection with both 1 and 2 doses of vaccine, against all variants. 170

However, there was significant heterogeneity across variants (P for heterogeneity < 0.001 for 171 both 1 and 2 doses), with highest efficacy after two doses seen against N501Y+ infection 172 (96.9%, 95% CI 96.7% to 97.1%), and lower efficacy seen against delta variant (66.1%, 95% CI 173 62.5% to 69.4%) ( Table 3) . 174 175 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268773 doi: medRxiv preprint

We find that in a large cohort of vaccinated individuals in Ontario, Canada vaccination 177 provided remarkable protection against breakthrough infection, with increased protection 178 afforded by a second vaccine dose relative to a single dose. We also find that maximal 179 protection against infection is provided 4-6 months after the second dose of vaccine, at which 180 time protection against infection was nearly complete. However, we found that infection risk 181 increased again after 6 months, suggesting the need for third vaccine doses at this interval (11) . 182 Consistent with effects demonstrated using viral neutralization assays (10) In summary, we use a case-cohort study with stratified person-time analysis of 208 vaccination status to demonstrate the strong protection afforded by SARS-CoV-2 vaccines in 209

Ontario, Canada. Despite this strong protection, we do find that an increase in hazard greater 210 than 6 months after second dose of vaccine; our analysis also suggests that increased intervals 211 between vaccine doses, as widely implemented in Canada, provides more durable protection 212 against infection than shorter dosing intervals. 213 214 Acknowledgements 215

The authors with to thank the staff at Public Health Ontario and Ontario's public health units for 216 collecting, sequencing, analyzing, and providing access to the data used for this analysis. 217 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268773 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268773 doi: medRxiv preprint 13 Vaccination status is treated as a time-varying covariate and defined by time since vaccination and cumulative doses, as described in the text. X-axis, person-time; Y-axis, cumulative incidence of infection. Shaded areas represent 95% confidence intervals.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268773 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268773 doi: medRxiv preprint 

Unprecedented achievement': who received the first billion COVID vaccinations? Nature

Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region

Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States. Health Aff (Millwood)

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease

Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22

The real-life impact of vaccination on COVID-19 mortality in Europe and Israel

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Myocarditis after

Covid-19 Vaccination in a Large Health Care Organization

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Booster shots for COVID-19-the debate continues

Population estimates

Ontario Agency for Health Protection and Promotion (Public Health Ontario)

Available via the Internet at publichealthontario.ca/-/media/documents/ncov/epi/covid-19-vaccine-uptake-ontario-episummary

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Alternative Dose Allocation Strategies to Increase Benefits From Constrained COVID-19 Vaccine Supply

Ontario Ministry of Health. COVID-19 Vaccine Bookings to Open For All Children

Available via the

Twodose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec

COVID-19 case age distribution: correction for differential testing by age

Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario

Ontario Ministry of Health

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Effectiveness of heterologous

and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

The copyright holder for this preprint this version posted January 5, 2022. ; https://doi.org/10.1101/2022.01.04.22268773 doi: medRxiv preprint